| UTHEALTH HOME ABOUT SBMI A-Z WEBMAIL INSIDE THE UNIVERSITY |
|
|||||||
|
Fusion Protein:MARK3-EXOSC10 |
Fusion Protein Summary |
 Fusion gene summary |
| Fusion partner gene information | Fusion gene name: MARK3-EXOSC10 | FusionPDB ID: 51765 | FusionGDB2.0 ID: 51765 | Hgene | Tgene | Gene symbol | MARK3 | EXOSC10 | Gene ID | 4140 | 5394 |
| Gene name | microtubule affinity regulating kinase 3 | exosome component 10 | |
| Synonyms | CTAK1|KP78|PAR1A|Par-1a|VIPB | PM-Scl|PM/Scl-100|PMSCL|PMSCL2|RRP6|Rrp6p|p2|p3|p4 | |
| Cytomap | 14q32.32-q32.33 | 1p36.22 | |
| Type of gene | protein-coding | protein-coding | |
| Description | MAP/microtubule affinity-regulating kinase 3C-TAK1ELKL motif kinase 2EMK-2cdc25C-associated protein kinase 1protein kinase STK10ser/Thr protein kinase PAR-1serine/threonine-protein kinase p78 | exosome component 10P100 polymyositis-scleroderma overlap syndrome-associated autoantigenautoantigen PM-SCLpolymyositis/scleroderma autoantigen 100 kDapolymyositis/scleroderma autoantigen 2 | |
| Modification date | 20200313 | 20200313 | |
| UniProtAcc | P27448 | Q01780 | |
| Ensembl transtripts involved in fusion gene | ENST ids | ENST00000216288, ENST00000303622, ENST00000335102, ENST00000416682, ENST00000429436, ENST00000440884, ENST00000553942, ENST00000561071, | ENST00000485606, ENST00000544779, ENST00000304457, ENST00000376936, |
| Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0) | * DoF score | 23 X 15 X 10=3450 | 10 X 11 X 7=770 |
| # samples | 25 | 16 | |
| ** MAII score | log2(25/3450*10)=-3.78659636189081 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | log2(16/770*10)=-2.2667865406949 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | |
| Context (manual curation of fusion genes in FusionPDB) | PubMed: MARK3 [Title/Abstract] AND EXOSC10 [Title/Abstract] AND fusion [Title/Abstract] | ||
| Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0) | MARK3(103928798)-EXOSC10(11137708), # samples:1 | ||
| Anticipated loss of major functional domain due to fusion event. | MARK3-EXOSC10 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. MARK3-EXOSC10 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF. MARK3-EXOSC10 seems lost the major protein functional domain in Hgene partner, which is a essential gene due to the frame-shifted ORF. MARK3-EXOSC10 seems lost the major protein functional domain in Hgene partner, which is a IUPHAR drug target due to the frame-shifted ORF. MARK3-EXOSC10 seems lost the major protein functional domain in Hgene partner, which is a kinase due to the frame-shifted ORF. MARK3-EXOSC10 seems lost the major protein functional domain in Tgene partner, which is a essential gene due to the frame-shifted ORF. | ||
| * DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
| Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
| Partner | Gene | GO ID | GO term | PubMed ID |
| Hgene | MARK3 | GO:0018105 | peptidyl-serine phosphorylation | 9543386 |
| Hgene | MARK3 | GO:0032092 | positive regulation of protein binding | 9543386 |
| Hgene | MARK3 | GO:0035331 | negative regulation of hippo signaling | 28087714 |
| Hgene | MARK3 | GO:0036289 | peptidyl-serine autophosphorylation | 9543386 |
| Fusion gene breakpoints across MARK3 (5'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
 |
| Fusion gene breakpoints across EXOSC10 (3'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
 |
Top |
Fusion Gene Sample Information |
| Fusion gene information from FusionGDB2.0. |
| Fusion gene information from two resources (ChiTars 5.0 and ChimerDB 4.0) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| Source | Disease | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| ChimerDB4 | Non-Cancer | ERR315491 | MARK3 | chr14 | 103928798 | + | EXOSC10 | chr1 | 11137708 | - |
Top |
Fusion ORF Analysis |
| Fusion information from ORFfinder translation from full-length transcript sequence from FusionPDB. |
| Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | Seq length (transcript) | BP loci (transcript) | Predicted start (transcript) | Predicted stop (transcript) | Seq length (amino acids) |
| ENST00000440884 | MARK3 | chr14 | 103928798 | + | ENST00000304457 | EXOSC10 | chr1 | 11137708 | - | 2112 | 1178 | 638 | 2011 | 457 |
| ENST00000440884 | MARK3 | chr14 | 103928798 | + | ENST00000376936 | EXOSC10 | chr1 | 11137708 | - | 2187 | 1178 | 638 | 2086 | 482 |
| ENST00000416682 | MARK3 | chr14 | 103928798 | + | ENST00000304457 | EXOSC10 | chr1 | 11137708 | - | 2120 | 1186 | 577 | 2019 | 480 |
| ENST00000416682 | MARK3 | chr14 | 103928798 | + | ENST00000376936 | EXOSC10 | chr1 | 11137708 | - | 2195 | 1186 | 577 | 2094 | 505 |
| ENST00000429436 | MARK3 | chr14 | 103928798 | + | ENST00000304457 | EXOSC10 | chr1 | 11137708 | - | 1984 | 1050 | 510 | 1883 | 457 |
| ENST00000429436 | MARK3 | chr14 | 103928798 | + | ENST00000376936 | EXOSC10 | chr1 | 11137708 | - | 2059 | 1050 | 510 | 1958 | 482 |
| ENST00000303622 | MARK3 | chr14 | 103928798 | + | ENST00000304457 | EXOSC10 | chr1 | 11137708 | - | 1963 | 1029 | 489 | 1862 | 457 |
| ENST00000303622 | MARK3 | chr14 | 103928798 | + | ENST00000376936 | EXOSC10 | chr1 | 11137708 | - | 2038 | 1029 | 489 | 1937 | 482 |
| ENST00000216288 | MARK3 | chr14 | 103928798 | + | ENST00000304457 | EXOSC10 | chr1 | 11137708 | - | 1644 | 710 | 170 | 1543 | 457 |
| ENST00000216288 | MARK3 | chr14 | 103928798 | + | ENST00000376936 | EXOSC10 | chr1 | 11137708 | - | 1719 | 710 | 170 | 1618 | 482 |
| ENST00000553942 | MARK3 | chr14 | 103928798 | + | ENST00000304457 | EXOSC10 | chr1 | 11137708 | - | 1519 | 585 | 45 | 1418 | 457 |
| ENST00000553942 | MARK3 | chr14 | 103928798 | + | ENST00000376936 | EXOSC10 | chr1 | 11137708 | - | 1594 | 585 | 45 | 1493 | 482 |
| ENST00000335102 | MARK3 | chr14 | 103928798 | + | ENST00000304457 | EXOSC10 | chr1 | 11137708 | - | 1543 | 609 | 0 | 1442 | 480 |
| ENST00000335102 | MARK3 | chr14 | 103928798 | + | ENST00000376936 | EXOSC10 | chr1 | 11137708 | - | 1618 | 609 | 0 | 1517 | 505 |
| DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated. |
| Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | No-coding score | Coding score |
| ENST00000440884 | ENST00000304457 | MARK3 | chr14 | 103928798 | + | EXOSC10 | chr1 | 11137708 | - | 0.00523876 | 0.9947613 |
| ENST00000440884 | ENST00000376936 | MARK3 | chr14 | 103928798 | + | EXOSC10 | chr1 | 11137708 | - | 0.006574867 | 0.99342513 |
| ENST00000416682 | ENST00000304457 | MARK3 | chr14 | 103928798 | + | EXOSC10 | chr1 | 11137708 | - | 0.006391981 | 0.993608 |
| ENST00000416682 | ENST00000376936 | MARK3 | chr14 | 103928798 | + | EXOSC10 | chr1 | 11137708 | - | 0.00571923 | 0.9942808 |
| ENST00000429436 | ENST00000304457 | MARK3 | chr14 | 103928798 | + | EXOSC10 | chr1 | 11137708 | - | 0.004276773 | 0.99572325 |
| ENST00000429436 | ENST00000376936 | MARK3 | chr14 | 103928798 | + | EXOSC10 | chr1 | 11137708 | - | 0.005255084 | 0.9947449 |
| ENST00000303622 | ENST00000304457 | MARK3 | chr14 | 103928798 | + | EXOSC10 | chr1 | 11137708 | - | 0.004096286 | 0.9959038 |
| ENST00000303622 | ENST00000376936 | MARK3 | chr14 | 103928798 | + | EXOSC10 | chr1 | 11137708 | - | 0.005034078 | 0.99496585 |
| ENST00000216288 | ENST00000304457 | MARK3 | chr14 | 103928798 | + | EXOSC10 | chr1 | 11137708 | - | 0.003510501 | 0.99648947 |
| ENST00000216288 | ENST00000376936 | MARK3 | chr14 | 103928798 | + | EXOSC10 | chr1 | 11137708 | - | 0.004145809 | 0.99585426 |
| ENST00000553942 | ENST00000304457 | MARK3 | chr14 | 103928798 | + | EXOSC10 | chr1 | 11137708 | - | 0.004289804 | 0.99571013 |
| ENST00000553942 | ENST00000376936 | MARK3 | chr14 | 103928798 | + | EXOSC10 | chr1 | 11137708 | - | 0.004905515 | 0.99509454 |
| ENST00000335102 | ENST00000304457 | MARK3 | chr14 | 103928798 | + | EXOSC10 | chr1 | 11137708 | - | 0.004472821 | 0.9955272 |
| ENST00000335102 | ENST00000376936 | MARK3 | chr14 | 103928798 | + | EXOSC10 | chr1 | 11137708 | - | 0.00367661 | 0.99632347 |
Top |
Fusion Amino Acid Sequences |
| For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among the all predicted ones. |
| >FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP >51765_51765_1_MARK3-EXOSC10_MARK3_chr14_103928798_ENST00000216288_EXOSC10_chr1_11137708_ENST00000304457_length(amino acids)=457AA_BP=180 MSTRTPLPTVNERDTENHTSHGDGRQEVTSRTSRSGARCRNSIASCADEQPHIGNYRLLKTIGKGNFAKVKLARHILTGREVAIKIIDKT QLNPTSLQKLFREVRIMKILNHPNIVKLFEVIETEKTLYLIMEYASGGEVFDYLVAHGRMKEKEARSKFRQIVSAVQYCHQKRIVHRDLK SEVAAGVKKSGPLPSAERLENVLFGPHDCSHAPPDGYPIIPTSGSVPVQKQASLFPDEKEDNLLGTTCLIATAVITLFNEPSAEDSKKGP LTVAQKKAQNIMESFENPFRMISNRWKLAQVQVQKDSKEAVKKKAAEQTAAREQAKEACKAAAEQAISVRQQVVLENAAKKRERATSDPR TTEQKQEKKRLKISKKPKDPEPPEKEFTPYDYSQSDFKAFAGNSKSKVSSQFDPNKQTPSGKKCIAAKKIKQSVGNKSMSFPTGKSDRGF -------------------------------------------------------------- >51765_51765_2_MARK3-EXOSC10_MARK3_chr14_103928798_ENST00000216288_EXOSC10_chr1_11137708_ENST00000376936_length(amino acids)=482AA_BP=180 MSTRTPLPTVNERDTENHTSHGDGRQEVTSRTSRSGARCRNSIASCADEQPHIGNYRLLKTIGKGNFAKVKLARHILTGREVAIKIIDKT QLNPTSLQKLFREVRIMKILNHPNIVKLFEVIETEKTLYLIMEYASGGEVFDYLVAHGRMKEKEARSKFRQIVSAVQYCHQKRIVHRDLK SEVAAGVKKSGPLPSAERLENVLFGPHDCSHAPPDGYPIIPTSGSVPVQKQASLFPDEKEDNLLGTTCLIATAVITLFNEPSAEDSKKGP LTVAQKKAQNIMESFENPFRMFLPSLGHRAPVSQAAKFDPSTKIYEISNRWKLAQVQVQKDSKEAVKKKAAEQTAAREQAKEACKAAAEQ AISVRQQVVLENAAKKRERATSDPRTTEQKQEKKRLKISKKPKDPEPPEKEFTPYDYSQSDFKAFAGNSKSKVSSQFDPNKQTPSGKKCI -------------------------------------------------------------- >51765_51765_3_MARK3-EXOSC10_MARK3_chr14_103928798_ENST00000303622_EXOSC10_chr1_11137708_ENST00000304457_length(amino acids)=457AA_BP=180 MSTRTPLPTVNERDTENHTSHGDGRQEVTSRTSRSGARCRNSIASCADEQPHIGNYRLLKTIGKGNFAKVKLARHILTGREVAIKIIDKT QLNPTSLQKLFREVRIMKILNHPNIVKLFEVIETEKTLYLIMEYASGGEVFDYLVAHGRMKEKEARSKFRQIVSAVQYCHQKRIVHRDLK SEVAAGVKKSGPLPSAERLENVLFGPHDCSHAPPDGYPIIPTSGSVPVQKQASLFPDEKEDNLLGTTCLIATAVITLFNEPSAEDSKKGP LTVAQKKAQNIMESFENPFRMISNRWKLAQVQVQKDSKEAVKKKAAEQTAAREQAKEACKAAAEQAISVRQQVVLENAAKKRERATSDPR TTEQKQEKKRLKISKKPKDPEPPEKEFTPYDYSQSDFKAFAGNSKSKVSSQFDPNKQTPSGKKCIAAKKIKQSVGNKSMSFPTGKSDRGF -------------------------------------------------------------- >51765_51765_4_MARK3-EXOSC10_MARK3_chr14_103928798_ENST00000303622_EXOSC10_chr1_11137708_ENST00000376936_length(amino acids)=482AA_BP=180 MSTRTPLPTVNERDTENHTSHGDGRQEVTSRTSRSGARCRNSIASCADEQPHIGNYRLLKTIGKGNFAKVKLARHILTGREVAIKIIDKT QLNPTSLQKLFREVRIMKILNHPNIVKLFEVIETEKTLYLIMEYASGGEVFDYLVAHGRMKEKEARSKFRQIVSAVQYCHQKRIVHRDLK SEVAAGVKKSGPLPSAERLENVLFGPHDCSHAPPDGYPIIPTSGSVPVQKQASLFPDEKEDNLLGTTCLIATAVITLFNEPSAEDSKKGP LTVAQKKAQNIMESFENPFRMFLPSLGHRAPVSQAAKFDPSTKIYEISNRWKLAQVQVQKDSKEAVKKKAAEQTAAREQAKEACKAAAEQ AISVRQQVVLENAAKKRERATSDPRTTEQKQEKKRLKISKKPKDPEPPEKEFTPYDYSQSDFKAFAGNSKSKVSSQFDPNKQTPSGKKCI -------------------------------------------------------------- >51765_51765_5_MARK3-EXOSC10_MARK3_chr14_103928798_ENST00000335102_EXOSC10_chr1_11137708_ENST00000304457_length(amino acids)=480AA_BP=203 MSTRTPLPTVNERDTENHTSHGDGRQEVTSRTSRSGARCRNSIASCADEQPHIGNYRLLKTIGKGNFAKVKLARHILTGREVAIKIIDKT QLNPTSLQKLFREVRIMKILNHPNIVKLFEVIETEKTLYLIMEYASGGEVFDYLVAHGRMKEKEARSKFRQGCQAGQTIKVQVSFDLLSL MFTFIVSAVQYCHQKRIVHRDLKSEVAAGVKKSGPLPSAERLENVLFGPHDCSHAPPDGYPIIPTSGSVPVQKQASLFPDEKEDNLLGTT CLIATAVITLFNEPSAEDSKKGPLTVAQKKAQNIMESFENPFRMISNRWKLAQVQVQKDSKEAVKKKAAEQTAAREQAKEACKAAAEQAI SVRQQVVLENAAKKRERATSDPRTTEQKQEKKRLKISKKPKDPEPPEKEFTPYDYSQSDFKAFAGNSKSKVSSQFDPNKQTPSGKKCIAA -------------------------------------------------------------- >51765_51765_6_MARK3-EXOSC10_MARK3_chr14_103928798_ENST00000335102_EXOSC10_chr1_11137708_ENST00000376936_length(amino acids)=505AA_BP=203 MSTRTPLPTVNERDTENHTSHGDGRQEVTSRTSRSGARCRNSIASCADEQPHIGNYRLLKTIGKGNFAKVKLARHILTGREVAIKIIDKT QLNPTSLQKLFREVRIMKILNHPNIVKLFEVIETEKTLYLIMEYASGGEVFDYLVAHGRMKEKEARSKFRQGCQAGQTIKVQVSFDLLSL MFTFIVSAVQYCHQKRIVHRDLKSEVAAGVKKSGPLPSAERLENVLFGPHDCSHAPPDGYPIIPTSGSVPVQKQASLFPDEKEDNLLGTT CLIATAVITLFNEPSAEDSKKGPLTVAQKKAQNIMESFENPFRMFLPSLGHRAPVSQAAKFDPSTKIYEISNRWKLAQVQVQKDSKEAVK KKAAEQTAAREQAKEACKAAAEQAISVRQQVVLENAAKKRERATSDPRTTEQKQEKKRLKISKKPKDPEPPEKEFTPYDYSQSDFKAFAG -------------------------------------------------------------- >51765_51765_7_MARK3-EXOSC10_MARK3_chr14_103928798_ENST00000416682_EXOSC10_chr1_11137708_ENST00000304457_length(amino acids)=480AA_BP=203 MSTRTPLPTVNERDTENHTSHGDGRQEVTSRTSRSGARCRNSIASCADEQPHIGNYRLLKTIGKGNFAKVKLARHILTGREVAIKIIDKT QLNPTSLQKLFREVRIMKILNHPNIVKLFEVIETEKTLYLIMEYASGGEVFDYLVAHGRMKEKEARSKFRQGCQAGQTIKVQVSFDLLSL MFTFIVSAVQYCHQKRIVHRDLKSEVAAGVKKSGPLPSAERLENVLFGPHDCSHAPPDGYPIIPTSGSVPVQKQASLFPDEKEDNLLGTT CLIATAVITLFNEPSAEDSKKGPLTVAQKKAQNIMESFENPFRMISNRWKLAQVQVQKDSKEAVKKKAAEQTAAREQAKEACKAAAEQAI SVRQQVVLENAAKKRERATSDPRTTEQKQEKKRLKISKKPKDPEPPEKEFTPYDYSQSDFKAFAGNSKSKVSSQFDPNKQTPSGKKCIAA -------------------------------------------------------------- >51765_51765_8_MARK3-EXOSC10_MARK3_chr14_103928798_ENST00000416682_EXOSC10_chr1_11137708_ENST00000376936_length(amino acids)=505AA_BP=203 MSTRTPLPTVNERDTENHTSHGDGRQEVTSRTSRSGARCRNSIASCADEQPHIGNYRLLKTIGKGNFAKVKLARHILTGREVAIKIIDKT QLNPTSLQKLFREVRIMKILNHPNIVKLFEVIETEKTLYLIMEYASGGEVFDYLVAHGRMKEKEARSKFRQGCQAGQTIKVQVSFDLLSL MFTFIVSAVQYCHQKRIVHRDLKSEVAAGVKKSGPLPSAERLENVLFGPHDCSHAPPDGYPIIPTSGSVPVQKQASLFPDEKEDNLLGTT CLIATAVITLFNEPSAEDSKKGPLTVAQKKAQNIMESFENPFRMFLPSLGHRAPVSQAAKFDPSTKIYEISNRWKLAQVQVQKDSKEAVK KKAAEQTAAREQAKEACKAAAEQAISVRQQVVLENAAKKRERATSDPRTTEQKQEKKRLKISKKPKDPEPPEKEFTPYDYSQSDFKAFAG -------------------------------------------------------------- >51765_51765_9_MARK3-EXOSC10_MARK3_chr14_103928798_ENST00000429436_EXOSC10_chr1_11137708_ENST00000304457_length(amino acids)=457AA_BP=180 MSTRTPLPTVNERDTENHTSHGDGRQEVTSRTSRSGARCRNSIASCADEQPHIGNYRLLKTIGKGNFAKVKLARHILTGREVAIKIIDKT QLNPTSLQKLFREVRIMKILNHPNIVKLFEVIETEKTLYLIMEYASGGEVFDYLVAHGRMKEKEARSKFRQIVSAVQYCHQKRIVHRDLK SEVAAGVKKSGPLPSAERLENVLFGPHDCSHAPPDGYPIIPTSGSVPVQKQASLFPDEKEDNLLGTTCLIATAVITLFNEPSAEDSKKGP LTVAQKKAQNIMESFENPFRMISNRWKLAQVQVQKDSKEAVKKKAAEQTAAREQAKEACKAAAEQAISVRQQVVLENAAKKRERATSDPR TTEQKQEKKRLKISKKPKDPEPPEKEFTPYDYSQSDFKAFAGNSKSKVSSQFDPNKQTPSGKKCIAAKKIKQSVGNKSMSFPTGKSDRGF -------------------------------------------------------------- >51765_51765_10_MARK3-EXOSC10_MARK3_chr14_103928798_ENST00000429436_EXOSC10_chr1_11137708_ENST00000376936_length(amino acids)=482AA_BP=180 MSTRTPLPTVNERDTENHTSHGDGRQEVTSRTSRSGARCRNSIASCADEQPHIGNYRLLKTIGKGNFAKVKLARHILTGREVAIKIIDKT QLNPTSLQKLFREVRIMKILNHPNIVKLFEVIETEKTLYLIMEYASGGEVFDYLVAHGRMKEKEARSKFRQIVSAVQYCHQKRIVHRDLK SEVAAGVKKSGPLPSAERLENVLFGPHDCSHAPPDGYPIIPTSGSVPVQKQASLFPDEKEDNLLGTTCLIATAVITLFNEPSAEDSKKGP LTVAQKKAQNIMESFENPFRMFLPSLGHRAPVSQAAKFDPSTKIYEISNRWKLAQVQVQKDSKEAVKKKAAEQTAAREQAKEACKAAAEQ AISVRQQVVLENAAKKRERATSDPRTTEQKQEKKRLKISKKPKDPEPPEKEFTPYDYSQSDFKAFAGNSKSKVSSQFDPNKQTPSGKKCI -------------------------------------------------------------- >51765_51765_11_MARK3-EXOSC10_MARK3_chr14_103928798_ENST00000440884_EXOSC10_chr1_11137708_ENST00000304457_length(amino acids)=457AA_BP=180 MSTRTPLPTVNERDTENHTSHGDGRQEVTSRTSRSGARCRNSIASCADEQPHIGNYRLLKTIGKGNFAKVKLARHILTGREVAIKIIDKT QLNPTSLQKLFREVRIMKILNHPNIVKLFEVIETEKTLYLIMEYASGGEVFDYLVAHGRMKEKEARSKFRQIVSAVQYCHQKRIVHRDLK SEVAAGVKKSGPLPSAERLENVLFGPHDCSHAPPDGYPIIPTSGSVPVQKQASLFPDEKEDNLLGTTCLIATAVITLFNEPSAEDSKKGP LTVAQKKAQNIMESFENPFRMISNRWKLAQVQVQKDSKEAVKKKAAEQTAAREQAKEACKAAAEQAISVRQQVVLENAAKKRERATSDPR TTEQKQEKKRLKISKKPKDPEPPEKEFTPYDYSQSDFKAFAGNSKSKVSSQFDPNKQTPSGKKCIAAKKIKQSVGNKSMSFPTGKSDRGF -------------------------------------------------------------- >51765_51765_12_MARK3-EXOSC10_MARK3_chr14_103928798_ENST00000440884_EXOSC10_chr1_11137708_ENST00000376936_length(amino acids)=482AA_BP=180 MSTRTPLPTVNERDTENHTSHGDGRQEVTSRTSRSGARCRNSIASCADEQPHIGNYRLLKTIGKGNFAKVKLARHILTGREVAIKIIDKT QLNPTSLQKLFREVRIMKILNHPNIVKLFEVIETEKTLYLIMEYASGGEVFDYLVAHGRMKEKEARSKFRQIVSAVQYCHQKRIVHRDLK SEVAAGVKKSGPLPSAERLENVLFGPHDCSHAPPDGYPIIPTSGSVPVQKQASLFPDEKEDNLLGTTCLIATAVITLFNEPSAEDSKKGP LTVAQKKAQNIMESFENPFRMFLPSLGHRAPVSQAAKFDPSTKIYEISNRWKLAQVQVQKDSKEAVKKKAAEQTAAREQAKEACKAAAEQ AISVRQQVVLENAAKKRERATSDPRTTEQKQEKKRLKISKKPKDPEPPEKEFTPYDYSQSDFKAFAGNSKSKVSSQFDPNKQTPSGKKCI -------------------------------------------------------------- >51765_51765_13_MARK3-EXOSC10_MARK3_chr14_103928798_ENST00000553942_EXOSC10_chr1_11137708_ENST00000304457_length(amino acids)=457AA_BP=180 MSTRTPLPTVNERDTENHTSHGDGRQEVTSRTSRSGARCRNSIASCADEQPHIGNYRLLKTIGKGNFAKVKLARHILTGREVAIKIIDKT QLNPTSLQKLFREVRIMKILNHPNIVKLFEVIETEKTLYLIMEYASGGEVFDYLVAHGRMKEKEARSKFRQIVSAVQYCHQKRIVHRDLK SEVAAGVKKSGPLPSAERLENVLFGPHDCSHAPPDGYPIIPTSGSVPVQKQASLFPDEKEDNLLGTTCLIATAVITLFNEPSAEDSKKGP LTVAQKKAQNIMESFENPFRMISNRWKLAQVQVQKDSKEAVKKKAAEQTAAREQAKEACKAAAEQAISVRQQVVLENAAKKRERATSDPR TTEQKQEKKRLKISKKPKDPEPPEKEFTPYDYSQSDFKAFAGNSKSKVSSQFDPNKQTPSGKKCIAAKKIKQSVGNKSMSFPTGKSDRGF -------------------------------------------------------------- >51765_51765_14_MARK3-EXOSC10_MARK3_chr14_103928798_ENST00000553942_EXOSC10_chr1_11137708_ENST00000376936_length(amino acids)=482AA_BP=180 MSTRTPLPTVNERDTENHTSHGDGRQEVTSRTSRSGARCRNSIASCADEQPHIGNYRLLKTIGKGNFAKVKLARHILTGREVAIKIIDKT QLNPTSLQKLFREVRIMKILNHPNIVKLFEVIETEKTLYLIMEYASGGEVFDYLVAHGRMKEKEARSKFRQIVSAVQYCHQKRIVHRDLK SEVAAGVKKSGPLPSAERLENVLFGPHDCSHAPPDGYPIIPTSGSVPVQKQASLFPDEKEDNLLGTTCLIATAVITLFNEPSAEDSKKGP LTVAQKKAQNIMESFENPFRMFLPSLGHRAPVSQAAKFDPSTKIYEISNRWKLAQVQVQKDSKEAVKKKAAEQTAAREQAKEACKAAAEQ AISVRQQVVLENAAKKRERATSDPRTTEQKQEKKRLKISKKPKDPEPPEKEFTPYDYSQSDFKAFAGNSKSKVSSQFDPNKQTPSGKKCI -------------------------------------------------------------- |
Top |
Fusion Protein Functional Features |
| Four levels of functional features of fusion genes Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr14:103928798/chr1:11137708) - FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels. - How to search 1. Put your fusion gene symbol. 2. Press the tab key until there will be shown the breakpoint information filled. 4. Go down and press 'Search' tab twice. 4. Go down to have the hyperlink of the search result. 5. Click the hyperlink. 6. See the FGviewer result for your fusion gene. |
 |
| Main function of each fusion partner protein. (from UniProt) |
| Hgene | Tgene |
| MARK3 | EXOSC10 |
| FUNCTION: Serine/threonine-protein kinase (PubMed:23666762). Involved in the specific phosphorylation of microtubule-associated proteins for MAP2 and MAP4. Phosphorylates the microtubule-associated protein MAPT/TAU (PubMed:23666762). Phosphorylates CDC25C on 'Ser-216'. Regulates localization and activity of some histone deacetylases by mediating phosphorylation of HDAC7, promoting subsequent interaction between HDAC7 and 14-3-3 and export from the nucleus (PubMed:16980613). Negatively regulates the Hippo signaling pathway and antagonizes the phosphorylation of LATS1. Cooperates with DLG5 to inhibit the kinase activity of STK3/MST2 toward LATS1 (PubMed:28087714). {ECO:0000269|PubMed:16980613, ECO:0000269|PubMed:23666762, ECO:0000269|PubMed:28087714}. | FUNCTION: Putative catalytic component of the RNA exosome complex which has 3'->5' exoribonuclease activity and participates in a multitude of cellular RNA processing and degradation events. In the nucleus, the RNA exosome complex is involved in proper maturation of stable RNA species such as rRNA, snRNA and snoRNA, in the elimination of RNA processing by-products and non-coding 'pervasive' transcripts, such as antisense RNA species and promoter-upstream transcripts (PROMPTs), and of mRNAs with processing defects, thereby limiting or excluding their export to the cytoplasm. The RNA exosome may be involved in Ig class switch recombination (CSR) and/or Ig variable region somatic hypermutation (SHM) by targeting AICDA deamination activity to transcribed dsDNA substrates. In the cytoplasm, the RNA exosome complex is involved in general mRNA turnover and specifically degrades inherently unstable mRNAs containing AU-rich elements (AREs) within their 3' untranslated regions, and in RNA surveillance pathways, preventing translation of aberrant mRNAs. It seems to be involved in degradation of histone mRNA. EXOSC10 has 3'-5' exonuclease activity (By similarity). EXOSC10 is required for nucleolar localization of C1D and probably mediates the association of MTREX, C1D and MPP6 wth the RNA exosome involved in the maturation of 5.8S rRNA. {ECO:0000250, ECO:0000269|PubMed:14527413, ECO:0000269|PubMed:16455498, ECO:0000269|PubMed:17412707, ECO:0000269|PubMed:17545563, ECO:0000269|PubMed:18172165, ECO:0000269|PubMed:19056938, ECO:0000269|PubMed:20368444, ECO:0000269|PubMed:20699273}. |
| Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at * Minus value of BPloci means that the break pointn is located before the CDS. |
| - Retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
| Hgene | MARK3 | chr14:103928798 | chr1:11137708 | ENST00000216288 | + | 7 | 16 | 62_70 | 180.0 | 714.0 | Nucleotide binding | ATP |
| Hgene | MARK3 | chr14:103928798 | chr1:11137708 | ENST00000303622 | + | 7 | 16 | 62_70 | 180.0 | 730.0 | Nucleotide binding | ATP |
| Hgene | MARK3 | chr14:103928798 | chr1:11137708 | ENST00000416682 | + | 8 | 17 | 62_70 | 203.0 | 753.0 | Nucleotide binding | ATP |
| Hgene | MARK3 | chr14:103928798 | chr1:11137708 | ENST00000429436 | + | 7 | 18 | 62_70 | 180.0 | 754.0 | Nucleotide binding | ATP |
| Hgene | MARK3 | chr14:103928798 | chr1:11137708 | ENST00000440884 | + | 7 | 16 | 62_70 | 180.0 | 660.0 | Nucleotide binding | ATP |
| Hgene | MARK3 | chr14:103928798 | chr1:11137708 | ENST00000553942 | + | 7 | 17 | 62_70 | 180.0 | 745.0 | Nucleotide binding | ATP |
| - Not-retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
| Hgene | MARK3 | chr14:103928798 | chr1:11137708 | ENST00000216288 | + | 7 | 16 | 326_365 | 180.0 | 714.0 | Domain | UBA |
| Hgene | MARK3 | chr14:103928798 | chr1:11137708 | ENST00000216288 | + | 7 | 16 | 56_307 | 180.0 | 714.0 | Domain | Protein kinase |
| Hgene | MARK3 | chr14:103928798 | chr1:11137708 | ENST00000216288 | + | 7 | 16 | 704_753 | 180.0 | 714.0 | Domain | KA1 |
| Hgene | MARK3 | chr14:103928798 | chr1:11137708 | ENST00000303622 | + | 7 | 16 | 326_365 | 180.0 | 730.0 | Domain | UBA |
| Hgene | MARK3 | chr14:103928798 | chr1:11137708 | ENST00000303622 | + | 7 | 16 | 56_307 | 180.0 | 730.0 | Domain | Protein kinase |
| Hgene | MARK3 | chr14:103928798 | chr1:11137708 | ENST00000303622 | + | 7 | 16 | 704_753 | 180.0 | 730.0 | Domain | KA1 |
| Hgene | MARK3 | chr14:103928798 | chr1:11137708 | ENST00000416682 | + | 8 | 17 | 326_365 | 203.0 | 753.0 | Domain | UBA |
| Hgene | MARK3 | chr14:103928798 | chr1:11137708 | ENST00000416682 | + | 8 | 17 | 56_307 | 203.0 | 753.0 | Domain | Protein kinase |
| Hgene | MARK3 | chr14:103928798 | chr1:11137708 | ENST00000416682 | + | 8 | 17 | 704_753 | 203.0 | 753.0 | Domain | KA1 |
| Hgene | MARK3 | chr14:103928798 | chr1:11137708 | ENST00000429436 | + | 7 | 18 | 326_365 | 180.0 | 754.0 | Domain | UBA |
| Hgene | MARK3 | chr14:103928798 | chr1:11137708 | ENST00000429436 | + | 7 | 18 | 56_307 | 180.0 | 754.0 | Domain | Protein kinase |
| Hgene | MARK3 | chr14:103928798 | chr1:11137708 | ENST00000429436 | + | 7 | 18 | 704_753 | 180.0 | 754.0 | Domain | KA1 |
| Hgene | MARK3 | chr14:103928798 | chr1:11137708 | ENST00000440884 | + | 7 | 16 | 326_365 | 180.0 | 660.0 | Domain | UBA |
| Hgene | MARK3 | chr14:103928798 | chr1:11137708 | ENST00000440884 | + | 7 | 16 | 56_307 | 180.0 | 660.0 | Domain | Protein kinase |
| Hgene | MARK3 | chr14:103928798 | chr1:11137708 | ENST00000440884 | + | 7 | 16 | 704_753 | 180.0 | 660.0 | Domain | KA1 |
| Hgene | MARK3 | chr14:103928798 | chr1:11137708 | ENST00000553942 | + | 7 | 17 | 326_365 | 180.0 | 745.0 | Domain | UBA |
| Hgene | MARK3 | chr14:103928798 | chr1:11137708 | ENST00000553942 | + | 7 | 17 | 56_307 | 180.0 | 745.0 | Domain | Protein kinase |
| Hgene | MARK3 | chr14:103928798 | chr1:11137708 | ENST00000553942 | + | 7 | 17 | 704_753 | 180.0 | 745.0 | Domain | KA1 |
| Tgene | EXOSC10 | chr14:103928798 | chr1:11137708 | ENST00000304457 | 13 | 24 | 503_583 | 583.0 | 861.0 | Domain | HRDC | |
| Tgene | EXOSC10 | chr14:103928798 | chr1:11137708 | ENST00000376936 | 13 | 25 | 503_583 | 583.0 | 886.0 | Domain | HRDC |
Top |
Fusion Protein-Protein Interaction |
| Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in |
| Protein-protein interactors with each fusion partner protein in wild-type from validated records (BIOGRID-3.4.160) |
| Gene | PPI interactors |
| Protein-protein interactors based on sequence similarity (STRING) |
| Gene | STRING network |
| MARK3 | |
| EXOSC10 |
| - Retained interactions in fusion protein (protein functional feature from UniProt). |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
| - Lost interactions due to fusion (protein functional feature from UniProt). |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
Related Drugs to MARK3-EXOSC10 |
| Drugs used for this fusion-positive patient. (Manual curation of PubMed, 04-30-2022 + MyCancerGenome) |
| Hgene | Tgene | Drug | Source | PMID |
Top |
Related Diseases to MARK3-EXOSC10 |
| Diseases that have this fusion gene. (Manual curation of PubMed, 04-30-2022 + MyCancerGenome) |
| Hgene | Tgene | Disease | Source | PMID |
| Diseases associated with fusion partners. (DisGeNet 4.0) |
| Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
Copyright 2021-Present -The University of Texas Health Science Center at Houston (UTHealth)
Web File Viewing | Emergency Information |Campus Carry|Site Policies